GB2594616A - Gaboxadol for reducing risk of suicide and rapid relief of depression - Google Patents

Gaboxadol for reducing risk of suicide and rapid relief of depression Download PDF

Info

Publication number
GB2594616A
GB2594616A GB2108720.0A GB202108720A GB2594616A GB 2594616 A GB2594616 A GB 2594616A GB 202108720 A GB202108720 A GB 202108720A GB 2594616 A GB2594616 A GB 2594616A
Authority
GB
United Kingdom
Prior art keywords
treatment
gaboxadol
pharmaceutically acceptable
suicide
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB2108720.0A
Other languages
English (en)
Other versions
GB202108720D0 (en
Inventor
Osten Pavel
Baldwin Kristin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Certego Therapeutics Inc
Original Assignee
Certego Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Certego Therapeutics Inc filed Critical Certego Therapeutics Inc
Publication of GB202108720D0 publication Critical patent/GB202108720D0/en
Publication of GB2594616A publication Critical patent/GB2594616A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GB2108720.0A 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression Withdrawn GB2594616A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770287P 2018-11-21 2018-11-21
PCT/US2019/062554 WO2020106927A1 (en) 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression

Publications (2)

Publication Number Publication Date
GB202108720D0 GB202108720D0 (en) 2021-08-04
GB2594616A true GB2594616A (en) 2021-11-03

Family

ID=70728606

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2108720.0A Withdrawn GB2594616A (en) 2018-11-21 2019-11-21 Gaboxadol for reducing risk of suicide and rapid relief of depression

Country Status (13)

Country Link
US (3) US20220008398A1 (https=)
EP (1) EP3883566A4 (https=)
JP (1) JP2022514194A (https=)
KR (1) KR20210110585A (https=)
CN (1) CN113395962A (https=)
AU (1) AU2019384157A1 (https=)
BR (1) BR112021009944A2 (https=)
CA (1) CA3120856A1 (https=)
GB (1) GB2594616A (https=)
IL (1) IL283311A (https=)
MX (1) MX2021005992A (https=)
SG (1) SG11202105358RA (https=)
WO (1) WO2020106927A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
KR20240157128A (ko) 2016-03-08 2024-10-31 세이지 테라퓨틱스, 인크. 신경활성 스테로이드, 조성물, 및 그의 용도
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
JP2022514194A (ja) * 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
JP2024020037A (ja) * 2022-08-01 2024-02-14 学校法人順天堂 痛みと痒みのバイオマーカー

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080159958A1 (en) * 2006-12-27 2008-07-03 Abbott Laboratories Determination of histamine-3 bioactivity
US20160228418A1 (en) * 2014-06-06 2016-08-11 Ovid Therapeutics Inc. Methods of increasing tonic inhibition and treating secondary insomnia
US20170020892A1 (en) * 2014-03-31 2017-01-26 University Of Maryland, Baltimore Use of negative modulators of gaba receptors containing alpha5 subunits as fast acting antidepressants
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment
US20170246152A1 (en) * 2015-07-17 2017-08-31 Ovid Therapeutics Inc. Methods of treating developmental disorders using gaboxadol

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
CL2004001603A1 (es) 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
TW200509918A (en) 2003-06-25 2005-03-16 Lundbeck & Co As H Treatment of depression and other affective disorders
TW200501951A (en) 2003-06-25 2005-01-16 Lundbeck & Co As H Treatment of neuropathic pain, fibromyalgia or rheumatoid arthritis
BRPI0410857A (pt) 2003-06-25 2006-07-04 Lundbeck & Co As H método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
US20050137222A1 (en) 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
JP2007530604A (ja) 2004-04-02 2007-11-01 ハー・ルンドベック・アクチエゼルスカベット 呼吸機能障害の治療
ZA200607427B (en) 2004-04-02 2009-02-25 Lundbeck & Co As H Treatment of impaired respiratory function with gaboxadol
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
GB0810063D0 (en) 2008-06-03 2008-07-09 Renovo Ltd Medicaments and methods for inhibition of scarring
EP2334299A1 (en) 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
WO2015171547A1 (en) 2014-05-05 2015-11-12 Ovid Therapeutics Inc. Methods of treating cognitive impairment associated with neurodegenerative disorders
US20170304358A1 (en) 2014-10-06 2017-10-26 Seyyed Nassir GHAEMI Primary and secondary prevention of dementias and suicide with trace dose lithium
LT3274331T (lt) 2015-03-24 2020-04-10 H. Lundbeck A/S 4,5,6,7-tetrahidroizozaksolo[5,4-c]piridin-3-olio gamybos būdas
WO2016176609A1 (en) 2015-04-30 2016-11-03 Ovid Therapeutics Inc Methods of treating prader-willi syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
AR105378A1 (es) 2015-07-17 2017-09-27 Ovid Therapeutics Inc Métodos de tratamiento de trastornos del desarrollo con gaboxadol
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
AR105670A1 (es) 2015-08-11 2017-10-25 Ovid Therapeutics Inc Métodos de sedación parenteral para usar durante el tratamiento de cuidados intensivos
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
JP6857647B2 (ja) 2015-08-11 2021-04-14 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
US20170119704A1 (en) 2015-10-13 2017-05-04 Ovid Therapeutics Inc. Treatment of cognitive impairment
WO2017205606A1 (en) 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
CN110225754A (zh) 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10737984B2 (en) 2016-11-30 2020-08-11 Hrl Laboratories, Llc Formulations and methods for 3D printing of ceramic matrix composites
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
CN110621318A (zh) 2017-03-15 2019-12-27 奥维德医疗公司 排他地由设计者药物激活的设计者受体在治疗癫痫发作紊乱中的用途
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
WO2018222957A1 (en) 2017-06-01 2018-12-06 Ovid Therapeutics Inc. Treatment of developmental disorders with imidazolone derivatives
WO2019006161A1 (en) 2017-06-28 2019-01-03 Ovid Therapeutics Inc. TREATMENT OF DEVELOPMENT SYNDROMES
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
AU2018320849A1 (en) 2017-08-25 2020-03-05 Ovid Therapeutics Inc. Recombinant adeno-associated vectors
JP2020533415A (ja) 2017-09-12 2020-11-19 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ナルコレプシーの処置におけるガボキサドールの使用
CN107595850A (zh) 2017-10-25 2018-01-19 桂林浩新科技服务有限公司 一种有效提高睡眠质量的药物组合物及其用途
JP2021521103A (ja) 2018-04-06 2021-08-26 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 物質使用障害の処置におけるガボキサドールの使用
JP2022514194A (ja) * 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080159958A1 (en) * 2006-12-27 2008-07-03 Abbott Laboratories Determination of histamine-3 bioactivity
US20170020892A1 (en) * 2014-03-31 2017-01-26 University Of Maryland, Baltimore Use of negative modulators of gaba receptors containing alpha5 subunits as fast acting antidepressants
US20160228418A1 (en) * 2014-06-06 2016-08-11 Ovid Therapeutics Inc. Methods of increasing tonic inhibition and treating secondary insomnia
US20170246152A1 (en) * 2015-07-17 2017-08-31 Ovid Therapeutics Inc. Methods of treating developmental disorders using gaboxadol
WO2017027249A1 (en) * 2015-08-11 2017-02-16 Ovid Therapeutics Inc. Methods of sedation and parenteral formulation for use during critical care treatment

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAO, Z et al., "Identifying Ketamine Responses in Treatment-Resistant Depression Using a Wearable Forehead EEG", IEEE Transactions on Biomedical Engineering, vol. 66, no. 6, June 2019 (Published online on 23.10.2018),DOI: 10.1109/TBME.2018.2877651; page 4, first paragraph; page 8, second paragraph *
DOMSCHKE, K et al., "Magnetoencephalographic Correlates of Emotional Processing in Major Depression Before and After Pharmacological Treatment", International Journal of Neuropsychopharmacology, (20150000), pages 1 - 9, Figure 2B *

Also Published As

Publication number Publication date
GB202108720D0 (en) 2021-08-04
US20200155522A1 (en) 2020-05-21
JP2022514194A (ja) 2022-02-10
KR20210110585A (ko) 2021-09-08
US20220054461A1 (en) 2022-02-24
AU2019384157A1 (en) 2021-06-17
US20220008398A1 (en) 2022-01-13
CA3120856A1 (en) 2020-05-28
CN113395962A (zh) 2021-09-14
EP3883566A1 (en) 2021-09-29
BR112021009944A2 (pt) 2021-08-17
WO2020106927A1 (en) 2020-05-28
SG11202105358RA (en) 2021-06-29
IL283311A (en) 2021-07-29
US11123332B2 (en) 2021-09-21
MX2021005992A (es) 2021-09-14
EP3883566A4 (en) 2022-09-07

Similar Documents

Publication Publication Date Title
GB2594616A (en) Gaboxadol for reducing risk of suicide and rapid relief of depression
JP2022514194A5 (https=)
Scorza et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study
US20190125789A1 (en) Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
JP2017526703A5 (https=)
US20110288134A1 (en) Composition and method for treating fibrosis
RU2012117563A (ru) Режим дозирования модулятора рецептора s1p
JP2020534362A (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
Barreto et al. Intratympanic corticosteroid for sudden hearing loss: does it really work?
AU2017279592A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
Gupta et al. Use of antiepileptic mood stabilizers in dermatology
Hunchaisri et al. Effectiveness of oral zinc supplementation in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL)
Milligan et al. A placebo-controlled trial of isoprinosine in patients with multiple sclerosis.
EP1032402B1 (en) Use of citicoline for the treatment of multiple sclerosis (MS)
AU2013323288B2 (en) Methods for alleviating symptoms of Multiple Sclerosis based on apoaequorin-containing compositions
Wright et al. Nialamide as a “Steroid Sparing” agent in the treatment of rheumatoid arthritis
El Ghazaly et al. Use of Oral Mini Pulse Dexamethasone in Vitiligo Patients
CN104041811A (zh) 一种改善男性性功能和精液品质的牛磺酸复合制剂
CN111743894A (zh) 倍半萜内酯类化合物在制备治疗视神经炎药物上的应用
Singh et al. Corticosteroids and their therapeutic applications in dentistry
Bordonaro et al. Fludarabine phosphate as an active and well tolerated salvage therapy in an elderly heavily pretreated Hodgkin's disease patient: a case report
Golubev et al. Parkon as a treatment of the Parkinson’s disease
EP3148530A1 (en) Methods for treating multiple sclerosis
Goverta et al. Dermatomyositis with Hepatic Impairment: A Rare and Intriguing Case Report Unveiling the Diagnostic Challenges and Treatment Dilemmas
Sopu Pipeline, novel, and future treatments for unipolar depression

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)